SANA · CIK 0001770121
What Sana Biotechnology, Inc. told the SEC could break it.
Sana's disclosures are those of a clinical-stage biotech years from market. It has never generated product revenue, posted a $244.2 million net loss in 2025 against a $1.8 billion accumulated deficit, and does not expect product sales for a number of years, if ever. Against that backdrop its operating risks are about dependence and exposure: it and its contract manufacturers rely on sole-source or limited suppliers for certain materials, reagents and equipment; its facilities sit in the earthquake- and wildfire-prone San Francisco Bay Area and Seattle with no earthquake insurance; and the FDA has stepped up scrutiny of foreign — especially China — drug manufacturing and the transfer of Americans' biological and genetic data abroad.
4 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Sole-source dependency
- sole-source suppliers for certain raw/intermediate materials and CDMO reagentshigh
Despite diversification efforts, Sana acquires certain raw and intermediate materials from sole suppliers, and it and its CDMOs rely on sole-source or limited vendors for key reagents, materials and equipment.
“although we strive to diversify our sources of raw and intermediate materials, in certain instances we acquire raw and intermediate materials from a sole supplier.”
SEC filing →As of 2026
Climate & physical
- HQ in earthquake/wildfire zones (SF Bay Area, Seattle); no earthquake insurancemedium
Sana's headquarters and facilities sit in the San Francisco Bay Area and Seattle, both exposed to wildfires and earthquakes, and the company carries no earthquake insurance.
“Our corporate headquarters and other facilities are located in areas that have experienced significant natural disasters, including the San Francisco Bay Area and Seattle, Washington, each of which has experienced severe effects from wildfires and, in the case of the San Francisco Bay Area, severe earthquakes. We do not carry earthquake insurance.”
SEC filing →As of 2026
Other disclosures
- pre-revenue; $1.8B accumulated deficit; years from commercializationmedium
Sana has never generated product revenue, posted a $244.2M FY2025 net loss and a $1.8B accumulated deficit, and does not expect product revenue for a number of years, if ever.
“We have not yet commercialized any products, and we do not expect to generate revenue from sales of any product candidates for a number of years, if ever.”
SEC filing →As of 2026
Regulatory & policy
- FDA scrutiny of China manufacturing & biological/genetic data transfermedium
The FDA has increased scrutiny of foreign (notably China) drug manufacturing and the transfer of Americans' biological materials and genetic data to parties in China, a risk for Sana's contractor network.
“The FDA has also increased its scrutiny of foreign drug manufacturing facilities and other contractors, in particular with respect to the transfer of Americans' biological materials and genetic and other sensitive data to parties located in China.”
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch